Vascular Solutions
AI-based software for cardiovascular pre-operational planning
Company profile
Company profile
Hi-D Imaging AG is a Swiss medical technology company specializing in AI-based cardiovascular imaging solutions and digital twin services for pre-operational planning. The company addresses the time-consuming manual work required before cardiac operations, including medical scan segmentation, multi-planar reconstruction, and anatomical measurements that traditionally suffer from up to 20% inter-observer and intra-observer variability. Their flagship product, 4TAVR, is an FDA 510(k) cleared software that provides automated, one-click solutions for structural heart intervention planning, particularly for transcatheter aortic valve replacement (TAVR) procedures. The software delivers all relevant procedure planning measurements and 3D volumes with unprecedented accuracy and speed. Beyond their imaging suite, Hi-D Imaging operates a Digital Twin Lab that creates patient-specific computational models to simulate blood flow under specified conditions. These digital twins help medical device manufacturers optimize product development timelines and costs, reducing the traditional 10+ year development cycle and expensive animal studies. The company's solutions are designed for seamless integration with no training requirements, featuring user-friendly interfaces that healthcare professionals can use within minutes. Hi-D Imaging serves cardiologists, medical device manufacturers, and researchers globally, with validated methods published in high-impact scientific journals. Their technology streamlines clinical workflows while maintaining the highest security standards and providing regular automated updates.
Company description Hi-D Imaging official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Other deployment with recorded integration context.
Company milestones
FDA 510(k) clearance for 4TAVR software (2024). Innosuisse Scale-Up Coaching program acceptance (2024). Innovation cheque project for next generation personalized artery models in silicone (2024).
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI-based software for cardiovascular pre-operational planning
AI-powered one-click solution for transcatheter aortic valve replacement planning
Patient-specific digital twins for cardiovascular blood flow analysis
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Annals of biomedical engineering · Mar 1, 2026
A fully automated artificial intelligence-driven software for planning of transcatheter aortic valve replacement.Cardiovascular revascularization medicine : including molecular interventions · Aug 1, 2024
In vitro investigation of the blood flow downstream of a 3D-printed aortic valve.Scientific reports · Jan 18, 2024
A comparative study on the analysis of hemodynamics in the athlete's heart.Scientific reports · Oct 5, 2022
Turbulent Kinetic Energy Loss and Shear Stresses Before and After Transcatheter Aortic Valve Replacement.JACC. Case reports · Mar 2, 2022
Toward an accurate estimation of wall shear stress from 4D flow magnetic resonance downstream of a severe stenosis.Magnetic resonance in medicine · Sep 1, 2021
Clinical validation
No linked records are currently available.
Regulatory
K241984 · 510k · Apr 2, 2025
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reduces up to 20% inter-observer and intra-observer variability in anatomical measurements
One-click solution for all relevant procedure planning measurements
Automates time-consuming manual segmentation and measurement tasks
Reduces traditional 10+ year medical device development timeline
Clinical partnership for structural heart interventions using AI technology for better patient care
Clinical partner in development of cutting-edge technology for structural heart team
05 · Leadership
Leadership profiles and professional links from the current Company record.
Utku Gülan
CEO
06 · Company updates
Recent articles published on Hi-D Imaging's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.